Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the... by Carlos Jimenez-Vicente, Aina Cardus, Sandra Castaño-Diez, Guillermo Ramil, Sara Garcia-Avila, Lucia Gomez-Perez, Daniel Esteban, Iago Arribas, Antonella Lucia Sturla, Monica Lopez-Guerra, Alexandra Martinez-Roca, Albert Cortes-Bullich, Amanda Isabel Perez-Valencia, Ines Zugasti, Ines Monge, Esther Carcelero, Ferran Vall-Llovera, Susana Vives, Jorge Sierra, Josep Nomdedeu, Guadalupe Oñate, Ana Garrido, Marta Pratcorona, Helena Pomares, Montserrat Arnan, Francesca Guijarro, Marina Diaz-Beya, Jordi Esteve, on behalf of the Spanish CETLAM Group

Get full text